Arcadia Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Arcadia Biosciences, Inc. (Nasdaq: RKDA) on February 6, 2026, reporting events occurring on February 4, 2026. The filing addresses corporate governance changes rather than financial performance.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to Item 5.02 regarding officer and director departures and does not contain financial statements or metrics.
Material Changes
The material change reported is the resignation of two directors from the Board of Directors effective February 4, 2026:
- Albert D. Bolles, Ph.D.: Resigned as a director and member of the Compensation Committee.
- Deborah Carosella: Resigned as a director and member of the Compensation Committee and Nominating and Governance Committee.
The Company stated that these resignations were not due to any disagreement with the Company or the Board regarding operations, policies, practices, or financial statements. Both individuals agreed to remain available to provide assistance as advisors.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the standard disclosure regarding the nature of the director resignations.
Key Facts for Investor Verification
- Verify the current composition of the Board of Directors following the resignations of Dr. Bolles and Ms. Carosella.
- Confirm whether the Board has initiated a search for replacement directors to fill the vacancies on the Compensation and Nominating and Governance Committees.
- Review subsequent filings to determine if the resignations impact the Company's ability to maintain Nasdaq listing requirements regarding independent directors.